Vanda Pharmaceuticals reported a net loss of $4.5 million for Q2 2024, compared to a net income of $1.5 million in Q2 2023. However, total revenues increased by 10% to $50.5 million compared to Q2 2023.
Total revenues for Q2 2024 were $50.5 million, a 10% increase compared to Q2 2023.
Fanapt® net product sales were $23.2 million, a 4% decrease compared to Q2 2023.
HETLIOZ® net product sales were $18.7 million, a 15% decrease compared to Q2 2023 due to generic competition.
PONVORY® net product sales were $8.6 million in the second quarter of 2024.
Vanda reinstates financial guidance and expects to achieve the following financial objectives in 2024:
Analyze how earnings announcements historically affect stock price performance